tetano
Editor, Senior Moderator
Signal Transduct Target Ther
. 2021 May 12;6(1):189.
doi: 10.1038/s41392-021-00604-5.
The interferon-stimulated exosomal hACE2 potently inhibits SARS-CoV-2 replication through competitively blocking the virus entry
Junsong Zhang[SUP] #[/SUP][SUP] 1 2 [/SUP], Feng Huang[SUP] #[/SUP][SUP] 2 3 [/SUP], Baijin Xia[SUP] 2 [/SUP], Yaochang Yuan[SUP] 2 [/SUP], Fei Yu[SUP] 1 2 [/SUP], Guanwen Wang[SUP] 1 [/SUP], Qianyu Chen[SUP] 1 [/SUP], Qian Wang[SUP] 1 [/SUP], Yuzhuang Li[SUP] 2 [/SUP], Rong Li[SUP] 2 [/SUP], Zheng Song[SUP] 2 [/SUP], Ting Pan[SUP] 2 4 [/SUP], Jingliang Chen[SUP] 2 5 [/SUP], Gen Lu[SUP] 6 [/SUP], Hui Zhang[SUP] 7 [/SUP]
Affiliations
Abstract
Since the outbreak of coronavirus disease 2019 (COVID-19), it has become a global pandemic. The spike (S) protein of etiologic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) specifically recognizes human angiotensin-converting enzyme 2 (hACE2) as its receptor, which is recently identified as an interferon (IFN)-stimulated gene. Here, we find that hACE2 exists on the surface of exosomes released by different cell types, and the expression of exosomal hACE2 is increased by IFN?/? treatment. In particular, exosomal hACE2 can specifically block the cell entry of SARS-CoV-2, subsequently inhibit the replication of SARS-CoV-2 in vitro and ex vivo. Our findings have indicated that IFN is able to upregulate a viral receptor on the exosomes which competitively block the virus entry, exhibiting a potential antiviral strategy.
. 2021 May 12;6(1):189.
doi: 10.1038/s41392-021-00604-5.
The interferon-stimulated exosomal hACE2 potently inhibits SARS-CoV-2 replication through competitively blocking the virus entry
Junsong Zhang[SUP] #[/SUP][SUP] 1 2 [/SUP], Feng Huang[SUP] #[/SUP][SUP] 2 3 [/SUP], Baijin Xia[SUP] 2 [/SUP], Yaochang Yuan[SUP] 2 [/SUP], Fei Yu[SUP] 1 2 [/SUP], Guanwen Wang[SUP] 1 [/SUP], Qianyu Chen[SUP] 1 [/SUP], Qian Wang[SUP] 1 [/SUP], Yuzhuang Li[SUP] 2 [/SUP], Rong Li[SUP] 2 [/SUP], Zheng Song[SUP] 2 [/SUP], Ting Pan[SUP] 2 4 [/SUP], Jingliang Chen[SUP] 2 5 [/SUP], Gen Lu[SUP] 6 [/SUP], Hui Zhang[SUP] 7 [/SUP]
Affiliations
- PMID: 33980808
- DOI: 10.1038/s41392-021-00604-5
Abstract
Since the outbreak of coronavirus disease 2019 (COVID-19), it has become a global pandemic. The spike (S) protein of etiologic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) specifically recognizes human angiotensin-converting enzyme 2 (hACE2) as its receptor, which is recently identified as an interferon (IFN)-stimulated gene. Here, we find that hACE2 exists on the surface of exosomes released by different cell types, and the expression of exosomal hACE2 is increased by IFN?/? treatment. In particular, exosomal hACE2 can specifically block the cell entry of SARS-CoV-2, subsequently inhibit the replication of SARS-CoV-2 in vitro and ex vivo. Our findings have indicated that IFN is able to upregulate a viral receptor on the exosomes which competitively block the virus entry, exhibiting a potential antiviral strategy.